Yaya Capital

What they fund

• Healthcare Value Chain Solutions — Companies providing solutions that improve access to healthcare and optimize costs, backed by high scientific validation. [1]
• MedTech Devices — Specifically, they conduct strategic allocation in medical assets to distribute MedTech devices in Brazilian territory. [1]
• Brazilian Healthcare Innovations — Ventures aiming to position Brazilian innovations globally through the exchange of goods with the US/EU. [1]

Credibility: The 'What We Do' section outlines their investment focus on thriving businesses with scientific validation and their specific interest in MedTech distribution and Brazilian innovation.

Investment thesis

Yaya Capital operates as a family office and venture firm focused on healthcare consolidation and cross-border innovation, leveraging a team of seasoned professionals to support companies through their evolution and expansion. [1]

• Healthcare Consolidation — The firm explicitly aims to help companies consolidate and grow within the healthcare sector, moving beyond simple capital injection to provide execution capabilities and network access. [1]
• Brazil-US/EU Bridge — A core strategic pillar involves amplifying Brazil’s access to top-tier medical care while positioning Brazilian healthcare innovations globally, specifically by expanding the exchange of goods between Brazil and the US/EU. [1]
• Scientific Rigor — The firm prioritizes businesses with a high level of scientific validation, investing in thriving businesses across different stages of development that offer solutions to the healthcare value chain. [1]

Credibility: The firm's own website details its philosophy, team composition, and specific strategic goals regarding healthcare consolidation and the Brazil-US/EU bridge.

Interconnection: The focus on scientific rigor and consolidation directly informs their investment stage, targeting established or rapidly scaling ventures rather than early-stage experimental projects.

Value add

Yaya Capital offers more than capital, leveraging a team of founders, executives, and advisors with extensive experience in technological, medical, scientific, and commercial domains. [1]

• Execution Capabilities — They employ their experience, network, and knowledge to support innovative businesses throughout their evolution and expansion journey. [1]
• Strategic Allocation — They actively conduct strategic allocation in medical assets to facilitate the distribution of MedTech devices in Brazil. [1]
• Global Network — Their team includes professionals with exposure to asset management, hospital chains, medical research, and business development, providing deep entrepreneurship experience. [1]

Fit verdict: Ideal for healthcare companies seeking consolidation support, international distribution partnerships (especially into Brazil or from Brazil to US/EU), and operational expertise from industry veterans.

Founder diligence script:

• How does Yaya Capital's network specifically facilitate the distribution of our MedTech device in Brazil?
• What is your typical involvement in the consolidation process for portfolio companies?
• Can you share examples of how your team's medical and scientific expertise has directly influenced a company's product development or regulatory strategy?
• How do you structure partnerships to amplify access to top-tier medical care in Brazil?
• What is your timeline for supporting a company's expansion into the US or EU markets?

Portfolio focus

The provided documents do not list specific portfolio companies, preventing a detailed cluster analysis.

Notable investments & exits

The provided documents do not list specific notable exits.

Strategic implications

Yaya Capital's unique positioning as a Brazil-US/EU bridge in healthcare creates a specialized moat, particularly for MedTech companies seeking Brazilian market entry or Brazilian innovators seeking global reach. [1] Their focus on 'consolidation' suggests they are well-suited for roll-up strategies in fragmented healthcare sub-sectors, potentially acting as a strategic buyer or aggregator. [1] The emphasis on 'scientific validation' may limit their deal flow to later-stage or more mature ventures, reducing risk but potentially missing early-stage breakthroughs.

Where they could go further

Yaya Capital could enhance its value proposition by publishing case studies demonstrating successful consolidations or cross-border MedTech distributions, thereby validating their execution capabilities to prospective founders. [1] Expanding their portfolio focus to include digital health and AI-driven diagnostics could capture emerging trends in the healthcare value chain, complementing their MedTech and device focus. [1] Establishing a formal co-investment fund or partnership with US/EU healthcare VCs could further solidify their role as a bridge, providing more structured pathways for Brazilian companies to access international capital and markets.